Diabetes

Six abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how different interventions or factors can impact type 2 diabetes (T2D) management.

Individuals who ate diets that aligned closer to DASH and Mediterranean guidelines had lower levels of plasminogen activator inhibitor-1 and homocysteine biomarkers.

Three posters presented at the American Diabetes Association 84th Scientific Sessions examined GLP-1 use and cardiovascular disease risk in several different patient populations.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.

Test your pharmacy news knowledge with our weekly quiz.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

Two abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how positive user experiences with a CGM can lead to better patient outcomes.

At the American Diabetes Association 84th Scientific Sessions, researchers presented findings from 4 studies that investigated the impact of various new diabetes technologies on managing the condition.

Access to diabetes self-management education and support services are crucial for improving diabetes outcomes.

Check out some of the latest research into diabetes medication options.

The Victoza generic is approved for use in adults and children aged 10 years and older.

Skin complications are common in patients with diabetes, but pharmacists can recommend several easy measures to help.

Two posters presented at ENDO 2024 assessed semaglutide’s impact on taste sensitivity and tirzepatide’s role in body weight reduction.

Clinical recommendations for the management of type 1 diabetes (T1D) in older adults are urgently needed as the global population ages and as improved diabetes care and management of complications have extended the life expectancy of the patient population.

The therapy from AstraZeneca is indicated to improve glycemic control in patients aged 10 years or older.

In a session presented at the 2024 Heart in Diabetes Conference, researchers discussed the abilities of continuous glucose monitoring (CGM) to capture lifestyle data and improve mortality rates.

Four poster presented at ENDO 2024 examined the current landscape of diabetes.

In an abstract presented at the Endocrine Society’s ENDO 2024 annual meeting in Boston, Massachusetts, researchers addressed the association between social vulnerability and glycemic control in patients with diabetes.

Research presented at ENDO 2024 found that glucagon-like peptide-1 receptor agonists had a lower acute pancreatitis recurrence risk than SGLT2i, DPP4i, and no medication.

In an abstract presented at the Endocrine Society’s ENDO 2024 annual meeting in Boston, Massachusetts, researchers explored access to GLP-1s for teenagers with and without type 2 diabetes.

Higher serum testosterone concentration was not associated with a reduced risk of developing type 2 diabetes in men older than 65.

Semaglutide reduced the risk of major kidney disease and cardiovascular (CV) events, and death from any cause, while simultaneously decelerating the loss of kidney function, among patients with type 2 diabetes (T2D) and CKD compared to placebo.

A poster presented at Digestive Disease Week showed that patients with MASLD taking semaglutide achieved significant weight loss while preserving skeletal muscle indices.

Test your pharmacy news knowledge with our weekly quiz.

Efsitora (efsitora alfa) from Eli Lilly met its primary endpoint of non-inferior A1C reduction compared to insulin degludec and insulin glargine in 2 phase 3 studies.

Researchers addressed the association of sleep quality and dietary intakes for patients with type 1 diabetes who use insulin pumps and continuous glucose monitoring.

Overall, older adults with diabetes faced a 53% higher risk of developing at least 1 functional limitation during the pandemic compared to older adults without diabetes.

With the judge’s failure to approve a settlement class, a $13.5 million settlement against Eli Lilly was called off.

A study from the Karolinska Institutet found that 76 out of 145410 patients treated with a GLP-1 developed thyroid cancer during nearly 4 years of follow-up.